Delving into the Latest Updates on Tinidazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitroimidazole, Timidazole, Tinidazole (JP17/USP/INN)

+ [17]

Target

DNA

Action

modulators

Mechanism

DNA modulators(DNA modulators)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersUrogenital Diseases

Active Indication

Bacterial VaginosisAmebiasisGiardiasis+ [4]

Inactive Indication-

Originator Organization

Zhejiang Sukean Pharmaceutical Co Ltd.

Active Organization

Mission Pharmacal Co.

Hologic, Inc.

Zhejiang Sukean Pharmaceutical Co Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1994),

Bacterial Infections

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC8H13N3O4S

InChIKeyHJLSLZFTEKNLFI-UHFFFAOYSA-N

CAS Registry19387-91-8

This randomized, open-label clinical trial will compare two bismuth-containing quadruple therapies for the first-line treatment of Helicobacter pylori infection. Adults aged 18 years or older with confirmed H. pylori infection who have not previously received eradication treatment will be randomly assigned in a 1:1 ratio to receive either a metronidazole-based regimen or a tinidazole-based regimen for 14 days. Both regimens will also include esomeprazole, tetracycline, and bismuth subcitrate.
The main purpose of the study is to determine whether the tinidazole-based regimen is not inferior to the metronidazole-based regimen in achieving successful H. pylori eradication. Eradication will be assessed after treatment using a carbon-13 urea breath test or an endoscopic urease test. The study will also compare adverse effects and treatment tolerability between the two groups. The results may help clinicians select the more appropriate nitroimidazole for bismuth quadruple therapy in routine clinical practice.

Start Date27 Jul 2026

Sponsor / Collaborator

University of Medicine & Pharmacy AT Ho Chi Minh City

ChiCTR2600132758

/ SuspendedNot ApplicableIIT

The efficacy and safety of high-dose dual therapy versus bismuth quadruple therapy in eradicating Helicobacter pylori in patients with type 2 diabetes: A randomized controlled non-inferiority study

Start Date01 Jan 2026

Sponsor / Collaborator-

NCT05383521

/ Unknown statusNot ApplicableIIT

Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis

We compare two oral tinidazole regimens for refractory trichomonas vaginitis.

Start Date01 Dec 2025

Sponsor / Collaborator

Peking University Shenzhen Hospital

100 Clinical Results associated with Tinidazole

Login to view more data

100 Translational Medicine associated with Tinidazole

Login to view more data

100 Patents (Medical) associated with Tinidazole

Login to view more data

1,781

Literatures (Medical) associated with Tinidazole

01 Dec 2026·JOURNAL OF PEPTIDE SCIENCE

Membrane Topology and Oligomerization of Peptaibols by Solid‐State NMR Spectroscopy

Review

Author: Bechinger, Burkhard ; Salnikov, Evgeniy S.

ABSTRACT:

Here, we review solid‐state NMR investigations of a variety of peptaibols in phospholipid bilayer environments. The peptides were prepared using different approaches such as microbial expression, solid‐phase peptide synthesis or the chemical synthesis in solution and a modular fragment condensation approach. Importantly, the techniques allowed the preparation of peptaibols labelled with 19 F as well as with 15 N either uniformly or specifically. In a first approach, 15 N‐labelled peptides were reconstituted into uniaxially oriented bilayers to determine membrane alignment, structure and tilt angles. Whereas alamethicin (20 residues) tends to adopt transmembrane orientations, shorter peptaibols such as zervamicin IIB, ampullosporin A and trichogin show increasing preference for orientations parallel to the membrane surface. In a second set of experiments, magic angle spinning solid‐state NMR spectroscopy experiments were performed. The CODEX experiments show the formation of oligomers in the membrane that increase in a concentration‐dependent manner. Whereas for alamethicin transmembrane dimers (P/L 1/30) and pentamers (1/13) were observed, trichogin occurs as in‐plane oriented tetramers (1/8). Interestingly, even the long alamethicin is oriented parallel to the membrane surface in a lipid composition mimicking bacterial membranes. These findings suggest that alternative mechanisms exist for the antimicrobial action of peptaibols.

01 Sep 2026·BIOPHYSICAL JOURNAL

Self-assembly of an 11-residue trichogin peptide and ion channel activity in phospholipid membranes

Article

Author: Wei, Chenyu ; Pohorille, Andrew

Short peptaibol peptides, such as the 11-residue trichogin, can permeabilize membranes and induce ion transport, providing insights into the evolution of ion channels as well as potential strategies for antimicrobial drug design. In this study, extensive molecular dynamics simulations at the microsecond timescale are applied to investigate the aggregation of trichogin in POPC membranes and the induced ion transport under an applied transmembrane voltage. The trichogin peptide is found to convert from a membrane surface-bound state to an inserted state, followed by self-assembly into a variety of N-mer clusters in the membrane, with populations of 17%, 22%, 20%, and 11% for 2-mer to 5-mer clusters, respectively, at a protein-to-lipid ratio of 1:10 under a 200-mV applied voltage. A diverse range of self-assembled structures is identified, from barrel-stave oligomers (dimer to hexamer) to more complex stacked oligomers built from head-to-tail dimers. The trimer is found to be the most populated oligomer and serves as a seed for higher-order assemblies. The ion transport mechanism is identified through direct ion-crossing events under applied voltage, where K⁺ and Cl^- ions traverse the membrane via transient, channel-like pentameric and hexameric barrel-stave bundles. An additional transport pathway is identified in which the translocation of lipid headgroups into the bilayer center stabilizes a transient pore along the lumen of a pentamer, resembling a toroidal pore. Stacked oligomers formed from head-to-tail dimers are shown to be unfavorable for ion transport due to misaligned hydrophilic faces, preventing the formation of a continuous water-filled lumen. The peptide assemblies are found to be highly dynamic, with rapid association and dissociation of peptide from a cluster and frequent interconversion between the surface-bound and membrane-inserted state. These dynamic properties make the short peptide assemblies flexible and functional, though less stable and less ion selective compared with complex ion channels formed of longer peptides.

01 Sep 2026·Acta Crystallographica Section C-Structural Chemistry

Multicomponent crystals of nitroimidazole drugs with trithiocyanuric acid: two competing drug–coformer supramolecular motifs

Article

Author: Rybarczyk-Pirek, Agnieszka J ; Chęcińska, Lilianna ; Hushcha, Valeryia

Cocrystal structures formed by trithiocyanuric acid (TTCA) and selected nitroimidazole derivatives, dimetridazole (DMZ·TTCA, C 5 H 7 N 3 O 2 ·C 3 H 3 N 3 S 3 ), tinidazole (TNZ·TTCA·MeOH, C 8 H 13 N 3 O 4 S·C 3 H 3 N 3 S 3 ·CH 3 OH), ornidazole (ONZ·TTCA·MeOH, C 7 H 10 ClN 3 O 3 ·C 3 H 3 N 3 S 3 ·CH 3 OH, and ONZ·TTCA·H 2 O, C 7 H 10 ClN 3 O 3 ·C 3 H 3 N 3 S 3 ·H 2 O) and ronidazole (RNZ·TTCA and 2RNZ·2TTCA, both C 6 H 8 N 4 O 4 ·C 3 H 3 N 3 S 3 ) were investigated to identify recurring drug–coformer aggregation patterns and factors determining supramolecular architecture. Structural analysis showed that TTCA adopts two principal supramolecular motifs: the hydrogen-bonded R22 (8) dimer and linear chain assemblies. Two dominant drug–coformer binding schemes were identified. The first involves N—H...N hydrogen bonding in the para position relative to the TTCA dimer, leading to four-molecule assemblies, which are accompanied by heteronuclear hydrogen bonding in the ortho position. The second motif is associated with TTCA linear chains, where drug molecules are linked through N—H...N interactions and further stabilized by direct intermolecular or solvent-mediated hydrogen bonding. The polymorphic structure 2RNZ·2TTCA combines both supramolecular strategies within a single-crystal architecture. Hirshfeld surface analysis and intermolecular energy calculations confirmed the importance of hydrogen-bond competition in determining the crystal packing and supramolecular organization in TTCA-based cocrystals.

4

News (Medical) associated with Tinidazole

03 Dec 2025

·pharma.economictimes.indiatimes.com

Par panel flags steep divergence in Drug Pricing; calls to review Trade margins

New Delhi: The Parliamentary Standing Committee on chemicals and fertilizers has flagged a ‘whopping difference’ between the prices at which drugs are sold to stockists and the prices charged to end-consumers, i.e., patients. The committee in its 14th report analyzing the impact of prise rise of medicines stated that many commonly prescribed medicines for everyday and chronic ailments are being sold at excessively high prices, with "unjustified trade margins" ranging from “600 per cent to 1100 per cent” over the price charged from stockist (PTS). Citing cases such as Ibrufen –anit-inflamaotry drug and Labocof – drug for cough and cold, the report suggest their the final market price is Rs. 4,560 and Rs. 2,850 respectively, however the the price charged from the stockists are Rs. 831 and Rs. 316, resulting in a steep difference of Rs. 3,729 and Rs. 2,534. Similarly, for Ciprofloxacin 500 mg and Tinidazole 600 mg—a common antibiotic FDC—the report notes that the medicine is supplied to stockists at a PTS of Rs 450, while its retail price is Rs. 3,500, reflecting a whopping difference of Rs. 3,050 The price to stockist refers to the amount charged by the drug marketer, while the Maximum Retail Price (MRP) is the amount paid by consumers. The MRP is determined after adding the margins of stockists, distributors and retailers, excluding taxes. According to the committee for drugs that fall under the non-scheduled and FDC category the steep divergence in the drugs initial and final prices is linked with a "loophole" in the country’s price control norms as the Drugs (Prices Control) Order of 2013 lacks control on trade margins, leavong room for widespread profiteering at the cost of patients. Secondly, under the present framework the price to stockist (PTS) data also remains undisclosed to the public, and fails to reveal the true extent of profiteering, it added. Presently, for non-scheduled formulations companies are permitted to increase the MRP of each product by up to 10 per cent annually, however as per the committee report, the absence of initial price fixation makes this control “largely meaningless and allows manufacturers to launch non-scheduled formulations, both branded and generic, at arbitrary points.” The Department of Pharmaceuticals (DoP) in its response when questioned about the wide gap between supplier prices and MRPs, cited distribution costs, which the committee has termed as unconvincing and has suggested to undertake a comprehensive review of the extant price regulation framework to plug the existing loopholes in the pricing mechanism. Seeking more clarity on the drug pricing and trade margins across the distribution chain, the committee recommended a DoP-led study to ascertain the factors driving the steep price hikes between the PTS and MRP. Meanwhile, in the absence of ceilings on trade margins it has also asked the drug price controller National Pharmaceutical Pricing Authority (NPPA), “to consider some appropriate control over prices of common non-scheduled formulations to obviate scope for abuse by manufacturers and marketers.” By Abhijeet Singh ,

03 Dec 2025

·pharma.economictimes.indiatimes.com

Par panel flags steep divergence in Drug Pricing; calls to review Trade margins

New Delhi: The Parliamentary Standing Committee on chemicals and fertilizers has flagged a ‘whopping difference’ between the prices at which drugs are sold to stockists and the prices charged to end-consumers, i.e., patients. The committee in its 14th report analyzing the impact of prise rise of medicines stated that many commonly prescribed medicines for everyday and chronic ailments are being sold at excessively high prices, with "unjustified trade margins" ranging from “600 per cent to 1100 per cent” over the price charged from stockist (PTS). Citing cases such as Ibrufen –anit-inflamaotry drug and Labocof – drug for cough and cold, the report suggest their the final market price is Rs. 4,560 and Rs. 2,850 respectively, however the the price charged from the stockists are Rs. 831 and Rs. 316, resulting in a steep difference of Rs. 3,729 and Rs. 2,534. Similarly, for Ciprofloxacin 500 mg and Tinidazole 600 mg—a common antibiotic FDC—the report notes that the medicine is supplied to stockists at a PTS of Rs 450, while its retail price is Rs. 3,500, reflecting a whopping difference of Rs. 3,050 The price to stockist refers to the amount charged by the drug marketer, while the Maximum Retail Price (MRP) is the amount paid by consumers. The MRP is determined after adding the margins of stockists, distributors and retailers, excluding taxes. According to the committee for drugs that fall under the non-scheduled and FDC category the steep divergence in the drugs initial and final prices is linked with a "loophole" in the country’s price control norms as the Drugs (Prices Control) Order of 2013 lacks control on trade margins, leavong room for widespread profiteering at the cost of patients. Secondly, under the present framework the price to stockist (PTS) data also remains undisclosed to the public, and fails to reveal the true extent of profiteering, it added. Presently, for non-scheduled formulations companies are permitted to increase the MRP of each product by up to 10 per cent annually, however as per the committee report, the absence of initial price fixation makes this control “largely meaningless and allows manufacturers to launch non-scheduled formulations, both branded and generic, at arbitrary points.” The Department of Pharmaceuticals (DoP) in its response when questioned about the wide gap between supplier prices and MRPs, cited distribution costs, which the committee has termed as unconvincing and has suggested to undertake a comprehensive review of the extant price regulation framework to plug the existing loopholes in the pricing mechanism. Seeking more clarity on the drug pricing and trade margins across the distribution chain, the committee recommended a DoP-led study to ascertain the factors driving the steep price hikes between the PTS and MRP. Meanwhile, in the absence of ceilings on trade margins it has also asked the drug price controller National Pharmaceutical Pricing Authority (NPPA), “to consider some appropriate control over prices of common non-scheduled formulations to obviate scope for abuse by manufacturers and marketers.” By Abhijeet Singh ,

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

100 Deals associated with Tinidazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01426	Tinidazole	G01AF21 P01AB02 J01XD02	DB00911

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Vaginosis	United States	Mission Pharmacal Co.	21 May 2007
Amebiasis	United States	Mission Pharmacal Co.	17 May 2004
Giardiasis	United States	Mission Pharmacal Co.	17 May 2004
Trichomonas Infections	United States	Mission Pharmacal Co.	17 May 2004
Bacterial Infections	China	Zhejiang Sukean Pharmaceutical Co Ltd.	01 Jan 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mycoplasma genitalium infection	Phase 2	United States	Hologic, Inc.	23 Jul 2025
non-gonococcal urethritis (NGU)	Phase 2	United States	Hologic, Inc.	23 Jul 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2025	Not Applicable	Helicobacter pylori infection First line	64,084	Quadruple-C+A+B	bhlqnhzehi(damxqexxiu) = wxfffbpwzc ipwbygdvjh (tgtwuisxtw ) View more	Positive	05 Oct 2025
				Single-capsule* 0.2% 0.2% 0.5% 14% 22%	bhlqnhzehi(damxqexxiu) = sytdjtxbbc ipwbygdvjh (tgtwuisxtw ) View more
NCT01481844 (Pubmed \| J Biol Chem \| PLoS One) Manual	Phase 3	Helicobacter pylori infection Second line	101	Lansoprazole+Amoxicillin Trihydrate+Clarithromycin+Tinidazole	lwwqsdoovv(skanrkxyhr) = ifxdswagdf onmjoedffa (zjxpnmcnbk )	Positive	28 Sep 2017
				Lansoprazole+Bismuth Subsalicylate+Metronidazole+Tetracycline Hydrochloride	lwwqsdoovv(skanrkxyhr) = gbukqsmrdm onmjoedffa (zjxpnmcnbk )
Pubmed \| Indian J Pharmacol	Not Applicable	Bacterial Vaginosis	344	Metronidazole (2 g)	drabmwogwx(jctmoafgky) = wjsljknuyc tdaoybbanb (atilhrwvns )	Positive	01 Mar 2012
				Tinidazole (2 g)	drabmwogwx(jctmoafgky) = uguzmmelbu tdaoybbanb (atilhrwvns )
NCT00334633 (CTgov)	Phase 4	Bacterial Vaginosis	593	tinidazole+metronidazole (Tinidazole 1 gm)	ypthzffuyo = yoeznprqao bflprlaqvo (hrjiqesoad, zxpdjljtsf - azvjwxdtqu) View more	-	23 Jun 2011
				tinidazole+metronidazole (Control)	aysorfuhca = rqkhqfuqcc binzrzhzef (wksjikfxfj, smdobiczjx - jnuxmgrsno)
NCT00229216 (Pubmed \| Obstet Gynecol)	Phase 3	Bacterial Vaginosis	235	Tinidazole 1 g once daily for 5 days	jdwnyfrnsm(rehbwucqko) = cxlatdqdln ipoatxvqht (tjvsierfmn )	-	01 Aug 2007
				Tinidazole 2 g once daily for 2 days	jdwnyfrnsm(rehbwucqko) = ckinaybect ipoatxvqht (tjvsierfmn )
NCT00313131 (Pubmed \| Bull World Health Organ)	Phase 3	Vaginal Discharge	1,570	Single-dose tinidazole plus fluconazole (TF)	eydmymafdy(sbvccwjaoo) = mincrgylfr imdhaftbrd (xqauinwlwc ) View more	Positive	01 Sep 2006
				Treatment for 7 days with metronidazole plus 3 days of treatment with vaginal clotrimazole (MC)	eydmymafdy(sbvccwjaoo) = veppivuqof imdhaftbrd (xqauinwlwc ) View more